Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Upacof Expectorant is a combination pharmaceutical product developed by Universal Corporation for the symptomatic relief of cough and respiratory congestion. The formulation contains four active ingredients: diphenhydramine hydrochloride, an antihistamine that provides antitussive effects by acting on the central nervous system and reducing allergic responses; ammonium chloride, an expectorant that increases the volume and decreases the viscosity of secretions in the respiratory tract; sodium citrate, which acts as a mucolytic agent; and menthol, which provides a cooling sensation to soothe the throat. It is primarily indicated for conditions such as the common cold, bronchitis, and other upper respiratory tract infections where cough and congestion are present. The product is approved and widely marketed in Kenya and other East African regions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphenhydramine + ammonium chloride + sodium citrate + menthol (Shanghai Universal Biotech).